obesity
OBESITY
Obesity is having an excessive amount of body fat that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include addressing the principal cause of weight gain and focusing management on both weight loss and patient-centered health outcomes.
A multidisciplinary approach, that is a combination of dietary change, physical activity and behavioral modification, is recommended.

Obesity Diagnosis

Diagnosis

History

  • Elicit the following in the history: Weight history, eating habits, physical activity, alcohol consumption, smoking, underlying diseases or conditions that hinder physical activities or weight loss, cultural and environmental factors affecting weight
  • Exclude secondary causes of obesity, such as medications (eg Insulin, Nateglinide, Repaglinide, Risperidone, Sertindole, Olanzapine, Clozapine, Mirtazapine, Valproate, Gabapentin), or history of genetic or endocrine disorders (eg hypothyroidism)
  • Detect potential comorbidities [eg type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, sleep apnea, hyperinsulinemia]
    • Its presence may affect the treatment decisions and outcomes
  • Assess mental status (eg patient’s self image, general mental health, stress factors, eating disorder, presence of depression and other mood disorders, substance abuse) and psychosocial barriers
  • Detect pregnancy/lactation in women
    • Not usually recommended for weight loss program
  • Family history (eg obesity, presence of cardiovascular disease, hypertension, DM, dyslipidemia, obesity-related cancer, thyroid disease)

Physical Examination

  • Blood pressure (BP) measurements in both arms
  • Physical exam for evidence of thyroid disease, Cushing’s syndrome, hypogonadism and dysmorphism

Anthropometry

  • Body Mass Index (BMI)
    • Measures relative weight for height
    • Indicates total body fat content
    • Helps predict future health status as raised BMI increases cardiovascular events or deaths, total mortality, DM, sleep disorder, osteoarthritis and certain cancers (eg endometrial, breast, colon, kidney, esophagus)
    • Done annually for screening and as needed for management
    • Calculated by the formula: BMI = weight (kg)/[height (m)]2
      • Asian countries have lower BMI cut-off points for overweight and obesity than the World Health Organization (WHO) BMI values
    • Calculation is for all age groups; BMI percentile for age is used in children <18 years old to determine the healthy weight status 
  • Waist Circumference
    • Useful measurement of intra-abdominal fat content before and during weight loss treatment
    • Technique of choice for classifying central obesity and clinical risk
    • A large waist circumference is associated with an increased risk for DM, dyslipidemia, hypertension and cardiovascular disease in patients who may not be considered obese by conventional BMI criteria

Laboratory Tests

  • To assess comorbidities associated with obesity
    • Lipid profile [eg low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG)]
    • Fasting glucose level, A1C, thyroid function tests
    • Uric acid, liver function (hepatic enzymes), renal function
    • Urine free cortisol levels (perform in patients with signs of Cushing’s syndrome)
    • Lab tests to rule out polycystic ovarian syndrome
    • Electrocardiogram (ECG)
    • Chest X-ray
    • Polysomnography and other sleep studies in patients at high risk for sleep apnea

Assessment

Risk Factor Assessment

Identify absolute risk status based on the presence of the following:

  • Disease Conditions
    • Coronary heart disease (CHD)
    • Atherosclerosis
    • Hypertension
    • Diabetes mellitus
    • Sleep apnea
    • Dyslipidemia
  • Other Obesity-Associated Diseases
    • Gynecological disorders (eg menorrhagia, amenorrhea)
    • Osteoarthritis
    • Asthma
    • Gallstones
    • Stress incontinence
    • Nonalcoholic fatty liver disease
    • Gastroesophageal reflux disease
  • Cardiovascular Risk Factors
    • Cigarette smoking
    • Hypertension
    • Hyperlipidemia
    • Impaired fasting glucose and impaired glucose tolerance
    • Family history of premature CHD [eg myocardial infarction (MI) or sudden death in father/male 1st-degree relative at ≤55 years or mother/female 1st-degree relative at ≤65 years]
    • Age ≥45 years for men or age ≥55 years for women or postmenopausal
  • Others
    • Physical inactivity
    • Elevated serum TG (>2.3 mmol/L) and decreased HDL-C

Classification

ADULT CLASSIFICATION OF WEIGHT BY BODY MASS INDEX
WHO Classification WHO BMI Cut-off Points (kg/m2) Risk of Comorbidities Asian BMI Cut-off Points (kg/m2)
Underweight <18.5 Low but increased risk of other clinical problems <18.5
Normal 18.5-24.9 Average 18.5-22.9
Overweight/Pre-obese 25.0-29.9 Increased 23.0-27.4
Obese Class I 30.0-34.9 Moderate 27.5-32.4
Obese Class II 35.0-39.9 Severe 32.5-37.4
Obese Class III ≥40.0 Very severe ≥37.5
Race High-Risk Waist Circumference (cm)
Men Women
Caucasians ≥102 ≥88
Asians ≥90 ≥80
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).